Abstract: It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.

Abstract: An apparatus management system, a management target apparatus, and a management method. The apparatus management system includes a plurality of management target apparatuses each configured to provide apparatus information of own apparatus and a communication terminal configured to receive apparatus status information included in the apparatus information received from each of the plurality of management target apparatuses, the apparatus status information indicating status of the management target apparatus, using a predetermined communication protocol.

Abstract: The present invention provides a method for selecting a cancer patient for whom a combination therapy with a retinoid and a cancer treatment agent is effective, which comprises a step of selecting a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma. In addition, the present invention provides a medicament which comprises a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma is a subject and is administered in combination of a retinoid and a cancer therapeutic agent.

Abstract: An apparatus management system, a management target apparatus, and a management method. The apparatus management system includes a plurality of management target apparatuses each configured to provide apparatus information of own apparatus and a communication terminal configured to receive apparatus status information included in the apparatus information received from each of the plurality of management target apparatuses, the apparatus status information indicating status of the management target apparatus, using a predetermined communication protocol.

Abstract: An information processing device includes circuitry to create, in an application execution environment, a container to provide a service. The application execution environment is used to provide the service and managed by units of containers. The circuitry causes the container to execute processing to provide the service and causes another device to record an execution time in association with identification information a user group. The execution time is a period of time during which the container executes the processing. The circuitry further obtains an amount value corresponding to usage of the service for the user group based on the execution time associated with the identification information of the user group.

Abstract: It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.

Abstract: An object is to provide a novel medical use of adipose tissue-derived mesenchymal stem cells. It was discovered that adipose tissue-derived mesenchymal stem cells (ASC) promote improvement of erectile dysfunction and recovery of the urge to urinate (improvement of sensory disorders of the lower urinary tract). On the basis of the discovery, a cell preparation containing adipose tissue-derived mesenchymal stem cells, which is effective to erectile dysfunction or sensory disorders of the lower urinary tract, is provided. In one embodiment, adipose tissue-derived mesenchymal stem cells and body fat are used in combination.

Abstract: An object is to provide a novel medical use of adipose tissue-derived mesenchymal stem cells. It was discovered that adipose tissue-derived mesenchymal stem cells (ASC) promote improvement of erectile dysfunction and recovery of the urge to urinate (improvement of sensory disorders of the lower urinary tract). On the basis of the discovery, a cell preparation containing adipose tissue-derived mesenchymal stem cells, which is effective to erectile dysfunction or sensory disorders of the lower urinary tract, is provided. In one embodiment, adipose tissue-derived mesenchymal stem cells and body fat are used in combination.

Abstract: An object is to provide a novel medical use of adipose tissue-derived mesenchymal stem cells. It was discovered that adipose tissue-derived mesenchymal stem cells (ASC) promote improvement of erectile dysfunction and recovery of the urge to urinate (improvement of sensory disorders of the lower urinary tract). On the basis of the discovery, a cell preparation containing adipose tissue-derived mesenchymal stem cells, which is effective to erectile dysfunction or sensory disorders of the lower urinary tract, is provided. In one embodiment, adipose tissue-derived mesenchymal stem cells and body fat are used in combination.